Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.50 |
| ▸ | CSGALNACT1 | Q8TDX6 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101558 | 0.85 | PTPN1 (0.64) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL1574756 | 0.83 | SMN1; SMN2 (0.59) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL17883944 | 0.83 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL4805 | 0.83 | RAB9A (0.69) | MEN1KMT2AALDH1A1MAPTRAB9A | |
| SCHEMBL20507158 | 0.83 | MEN1 (0.49) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL17652591 | 0.83 | MAPT (0.60) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL18460610 | 0.83 | MEN1 (0.63) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL23930594 | 0.81 | RAB9A (0.50) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL9373896 | 0.81 | SMN1; SMN2 (0.47) | MEN1KMT2AALDH1A1MAPTLMNA | |
| SCHEMBL5802479 | 0.80 | MEN1 (0.52) | MEN1KMT2AALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-8809372-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2760833-A1 | PYRIDINE DERIVATIVES | Endo Pharmaceuticals Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2760854-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | Endo Pharmaceuticals Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049565-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085148-A1 | Pyridine Derivatives | CYP2A7, CYP21A2, CYP3A7 | MEN1 3533/4885KMT2A 2460/4885ALDH1A1 165/4885 |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | CYP21A2, CYP26A1, CYP11B1 | MEN1 3281/4885KMT2A 2239/4885ALDH1A1 87/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | MEN1 2441/4885KMT2A 2981/4885ALDH1A1 493/4885 |
| US-20160340310-A9 | Pyridine Derivatives | CYP2A7, CYP21A2, CYP3A7 | MEN1 3533/4885KMT2A 2460/4885ALDH1A1 165/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | MEN1 3830/4885KMT2A 2437/4885ALDH1A1 2324/4885 |
| US-20130085164-A1 | Imidazole Derivatives | CYP17A1, CYP2A7, CYP11B1 | MEN1 2644/4885KMT2A 1810/4885ALDH1A1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.